Edition:
United Kingdom

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

5.00USD
7 Dec 2018
Change (% chg)

$-0.04 (-0.79%)
Prev Close
$5.04
Open
$5.02
Day's High
$5.09
Day's Low
$4.94
Volume
261,037
Avg. Vol
393,618
52-wk High
$17.30
52-wk Low
$4.20

Latest Key Developments (Source: Significant Developments)

LFB Biotechnologies Cuts Stake In TG Therapeutics To 3.4 Pct As Of July 6, From 9.8 Pct As Of May 15 - SEC Filing
Wednesday, 11 Jul 2018 

July 11 (Reuters) - TG Therapeutics Inc ::LFB BIOTECHNOLOGIES, S.A.S.U. CUTS STAKE IN TG THERAPEUTICS INC TO 3.4 PERCENT AS OF JULY 6 FROM A STAKE OF 9.8 PERCENT AS OF MAY 15 - SEC FILING.  Full Article

TG Therapeutics Files Prospectus Supplement Related To Resale Of 216,294 Common Shares
Monday, 9 Jul 2018 

July 9 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS FILES PROSPECTUS SUPPLEMENT RELATED TO RESALE OF 216,294 COMMON SHARES BY THE SELLING SHAREHOLDER - SEC FILING.  Full Article

TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES.TG THERAPEUTICS INC - ‍ UNDER TERMS, HENGRUI WILL RECEIVE AN UP-FRONT LICENSING FEE AND NEAR-TERM MILESTONES, PAYABLE IN TG COMMON STOCK​.TG THERAPEUTICS INC - ‍HENGRUI IS ELIGIBLE TO RECEIVE COLLABORATION AND LICENSING PAYMENTS OF ABOUT $350 MILLION, IN ADDITION TO ROYALTIES ON FUTURE SALES​.  Full Article

TG Therapeutics Announces Initiation Of Randomized Phase II Trial In Follicular Lymphoma
Monday, 27 Nov 2017 

Nov 27 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS ANNOUNCES INITIATION OF NATIONAL CANCER INSTITUTE/SWOG-SPONSORED RANDOMIZED PHASE II TRIAL IN FOLLICULAR LYMPHOMA.  Full Article

TG Therapeutics qtrly net loss per common share $0.48
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - TG Therapeutics Inc ::TG therapeutics, inc. Provides business update and reports third quarter 2017 financial results.TG therapeutics inc - qtrly net loss per common share $0.48.Q3 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.TG therapeutics inc - believes cash and cash equivalents will be sufficient to fund planned operations through 2018​.  Full Article

TG Therapeutics announces completion of full enrollment in UNITY-CLL phase 3 trial
Monday, 16 Oct 2017 

Oct 16 (Reuters) - TG Therapeutics Inc : :TG Therapeutics announces completion of full enrollment in the UNITY-CLL phase 3 trial.TG Therapeutics Inc - ‍targeting an NDA/BLA filing for combination of TGR-1202 + TG-1101 in 2H18​.TG Therapeutics Inc - ‍top-line ORR data from UNITY-CLL trial expected in 2Q18​.  Full Article

TG Therapeutics ‍says FDA confirms accelerated approval for TG-1101 based on overall response rate a review issue
Monday, 16 Oct 2017 

Oct 16 (Reuters) - TG Therapeutics Inc : :TG Therapeutics provides update on fda meeting for genuine phase 3 trial.TG Therapeutics - co ‍has met with U.S. FDA regarding use of results from genuine phase 3 trial to support bla filing for approval of TG-1101​.TG Therapeutics Inc - ‍fda confirmed that accelerated approval for TG-1101 based on overall response rate would be a review issue ​.TG Therapeutics - ‍FDA asked co to consider future available therapy in risk/benefit analysis in future BLA filing that may impact accelerated approval.TG Therapeutics - co, FDA also discussed potential use of progression free survival results from genuine trial to support full approval of TG-1101​.TG Therapeutics Inc - ‍plans to have a follow-up meeting with FDA to discuss use of PFs endpoint in more detail before end of year​.  Full Article

BRIEF-TG Therapeutics, Novimmune Announce Global Agreement For Development And Commercialization Of Anti-CD47/ Anti-CD19 bispecific antibody

* TG THERAPEUTICS AND NOVIMMUNE SA ANNOUNCE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF A NOVEL ANTI-CD47/ ANTI-CD19 BISPECIFIC ANTIBODY